Send to:

Choose Destination
See comment in PubMed Commons below
BMJ Case Rep. 2012 May 8;2012. pii: bcr1020115052. doi: 10.1136/bcr.10.2011.5052.

Intravenous immunoglobulin in treatment of Clostridium difficile colitis.

Author information

  • 1Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, Illinois, USA.


Clostridium difficile infection is the most common infectious cause of healthcare-acquired diarrhoea. Severe infections cause therapeutic challenges for healthcare providers. Various novel treatment modalities are currently being explored for treatment of severe disease. The authors report a 70-year-old female who presented to the emergency room with 1 week history of fever, watery diarrhoea, diffuse abdominal pain and weakness. C difficile toxin was detected in the stool and abdominal CAT scan showed extensive colonic wall thickening. The patient was started on intravenous metronidazole along with oral vancomycin. Due to the severity of the infection the patient was given intravenous immunoglobin for 4 consecutive days. The patient had vast improvement in her clinical symptoms with resolution of the multi-organ system failure. It is currently considered that the predominant intravenous immunoglobin's mechanism of action is through binding and neutralisation of toxin A by IgG antitoxin A antibodies.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk